Is Celldex Therapeutics, Inc. (CLDX) Stock Positioned for Growth Ahead of Potential 2027 Approval?
TheFly reported on June 10 that UBS increased its price target on CLDX to $45 from $38 while maintaining a Buy rating on the shares.
Celldex Therapeutics Inc. (CLDX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Kynam Capital Derrick Tang | 5,840,567 | $185,262,785 | -2% | 11.43% |
| 2. | Point72 Asset Management Steve Cohen | 3,229,939 | $102,453,665 | +84% | 0.13% |
| 3. | Commodore Capital Egen Atkinson And Michael Kramarz | 2,696,616 | $85,536,660 | +6% | 4.95% |
| 4. | Eversept Partners Kamran Moghtaderi | 1,788,016 | $56,715,868 | +25% | 2.99% |
| 5. | Braidwell LP Alex Karnal | 1,356,082 | $43,014,921 | -28% | 1.43% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $26.82 | 11,500 | $308,430.00 | 40,284 | 2024-11-11 | Filing | |
| $46.28 | 430 | $19,900.40 | 430 | 2021-08-11 | Filing | |
| $4.73 | 2,115 | $10,003.95 | 2,115 | 2020-06-11 | Filing | |
| $4.83 | 1,050 | $5,071.50 | 1,367 | 2020-06-10 | Filing | |
| $3.01 | 1,000 | $3,005.00 | 1,000 | 2020-06-09 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $29.10 | 4,166 | $121,209.77 | 30,796 | 2025-12-04 | Filing | |
| $24.00 | 49,298 | $1,183,176.65 | 20,833 | 2025-11-13 | Filing | |
| $25.42 | 430 | $10,928.45 | 34,962 | 2025-08-13 | Filing | |
| $23.95 | 341 | $8,167.46 | 35,392 | 2025-08-13 | Filing | |
| $35.42 | 17,172 | $608,314.67 | 28,125 | 2024-06-14 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 689 | $25,638 | 0% | |
| 2. | 18 | $670 | 0% |
News See All
10 Best Biotech Stocks to Buy According to Analysts
Biotechnology is enjoying one of its strongest years in recent times, which is mostly fueled by a rebound in capital markets, rising merger activity, and renewed investor confidence.
Celldex Therapeutics, Inc. (CLDX): A Bull Case Theory
We came across a bullish thesis on Celldex Therapeutics, Inc. on X.com by @MoneyShow. In this article, we will summarize the bulls’ thesis on CLDX.
Barclays Lifts PT on Celldex Therapeutics (CLDX) to $24 From $21
Celldex Therapeutics, Inc. (NASDAQ:CLDX) is one of the best small cap stocks to buy with huge upside potential. Barclays lifted the price target on Celldex Therapeutics, Inc.
12 Small Cap Stocks to Buy with Huge Upside Potential
Talking about rotation in the market, she expects the trend to continue for a while, with the capital basically moving from the high multiple mega cap winners towards small caps, cyclicals, and the international...
Barclays Initiates Coverage of Celldex Therapeutics (CLDX) With an Underweight Rating
Celldex Therapeutics, Inc. (NASDAQ:CLDX) is one of the best small cap stocks with the highest upside. Barclays initiated coverage of Celldex Therapeutics, Inc.
11 Best Small Cap Stocks with the Highest Upside
She stated that small caps show possibility, as a lot of them are rate sensitive, a little bit more levered, and are helped by lower rates, which is why there has been a lot of momentum behind small caps...
LifeSci Capital Maintains a Buy on Celldex Therapeutics (CLDX), Keeps the PT
Celldex Therapeutics, Inc. (NASDAQ:CLDX) is one of the Best Small-Cap Growth Stocks to Buy Right Now.
11 Best Small-Cap Growth Stocks to Buy Right Now
On August 14, Jonathan Krinsky of BTIG joined CNBC for an interview to discuss the sustainability of the recent small-cap rally.
10 Best Cancer Stocks to Invest in for Long-Term Gains
After cardiovascular disease, cancer is the second most common cause of mortality worldwide.
Hedge Fund Resource Center